Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with Hepatocellular Carcinoma. This retrospective, observational study included clinicopathological and follow-up data of patients with Hepatocellular Carcinoma who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.
Study Type
OBSERVATIONAL
Enrollment
300
Henan cancer hosiptal
Zhengzhou, Henan, China
RECRUITINGThe difference in overall survival between the two groups calculated by Kaplan-Meier
Survival differences between the monotherapy and combination groups
Time frame: 2021.7-2021.12
The difference of overall survival in patients receiving different doses of regorafenib
In the real world, regorafenib was used in different dosages: 40mg,80mg,120mg,160mg,respectively. The difference in overall survival time of patients with different dosage was compared.
Time frame: 2021.11-2021.12
Regorafenib in combination with other drugs
In the real world, regorafenib was used in combination with chemotherapy, immunotherapy or other drugs, and the frequency of occurrence of different conditions was analyzed.
Time frame: 2021.7-2021.10
Survival differences among the patients with different clinical phenotypes and genotypes
To compare the survival of patients with Hepatocellular Carcinoma by gender, age, tumor site and other genotypes
Time frame: 2021.7-2021.10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.